Related Experiment Videos
Lipid-lowering trials: results and limitations
1Department of Public Health Sciences, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC 27157-1063.
American Heart Journal
|December 1, 1994
Summary
Lipid-lowering therapies reduce coronary heart disease incidence. Combined data from over 45,000 participants show benefits after a two-year delay, despite trial limitations.
Area of Science:
- Cardiology
- Preventive Medicine
- Clinical Trials
Background:
- Lipid accumulation is central to coronary atherosclerosis development and progression.
- Numerous clinical trials have investigated lipid-lowering interventions since the 1960s.
- Data encompasses over 45,000 participants, primarily men.
Purpose of the Study:
- To review combined results of lipid-lowering trials.
- To address ongoing debates regarding therapy benefits, considering methodological limitations.
Main Methods:
- Review of published and non-published meta-analyses of lipid-lowering trials.
- Analysis of data from extensive clinical trials.
Main Results:
- Despite methodological limitations in individual trials, combined data demonstrate a reduction in coronary heart disease incidence.
- A lag time of two or more years is observed before benefits become apparent.
Conclusions:
- Lipid-lowering therapy demonstrates a reduction in coronary heart disease incidence.
- Acknowledging trial limitations, the collective evidence supports the benefits of lipid-lowering interventions.